First, to assess the efficiency of CO-RBCs in delivering CO to the liver, we administered CO-RBCs to healthy and MCDD-induced MASH model mice at a dose of 1400 mg Hb/kg, and then monitored liver CO levels 90 min later. This evidence concerns the gene GSTM1 and metabolic dysfunction-associated steatohepatitis.